Recently I blogged about Biotech company Seattle Genetics and their emerging treatment for both Hodgkin’s and anaplastic large cell lymphoma, a drug currently called SGN-35.
Good news this week: both the FDA and the European Medicines Agency have given SGN-35 what’s known as orphan drug status. An orphan drug is in general defined as a drug so specialized that it only treats a disease affecting a very small portion of the population. The designation is somewhat rare, and for the pharmaceutical company, an absolute boon: In the US, the status confers a number of both financial and legal incentives for the company to test, produce and market a drug that would otherwise be cost-prohibitive.
What this means is that Seattle Genetics can really get the ball rolling on SGN-35 without fear of competition and with the help of government subsidies, among other things. While it’s all a bit more complicated that this, and while it might fundamentally seem to violate the principles of a free market, we can’t look at it this way.
Rather, we should look at it as an interventionalist health policy that eschews lengthy red tape on behalf of those patients whom the drug can benefit the most.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...